# Amplifying radiation-induced anti-tumor immunity: the dual role of brachytherapy and low-dose total body irradiation

**Authors:** YingQi Gu, Yang Yang, Jian Gao, ZhouXue Wu, Jia Wang, Chen Xie, XinYi Wang, Min Wu, YunXue Zheng, XiaoYin Zhang, Yue Chen, ShaoZhi Fu, JingBo Wu

PMC · DOI: 10.3389/fimmu.2026.1771593 · Frontiers in Immunology · 2026-02-17

## TL;DR

This study shows that brachytherapy, combined with low-dose whole-body radiation, enhances anti-tumor immunity more effectively than traditional radiotherapy.

## Contribution

The novel finding is that brachytherapy combined with low-dose total body irradiation amplifies systemic immune activation against tumors.

## Key findings

- Hypo-fractionated brachytherapy inhibited tumor growth more effectively than external beam radiotherapy.
- Brachytherapy significantly modulated immune cells in the tumor microenvironment.
- Low-dose total body irradiation at 0.1 Gy enhanced brachytherapy's immunological effects and triggered systemic immune activation.

## Abstract

Radiotherapy can be a vaccine by triggering patients’ prophylactic tumor-specific immune responses. Brachytherapy has biological and physical benefits over external beam radiation. Low-dose total body irradiation can produce systemic immunity. We hypothesized that brachytherapy more effectively modulates immunity than external beam radiotherapy, with low-dose total body irradiation amplifying this effect.

After creating the Lewis lung cancer model, we compared hypo-fractionated brachytherapy with hypo-fractionated radiotherapy, examining immunogenic cell death, DNA damage, cell proliferation and immune cells in tumor. We then evaluated if low-dose whole-body irradiation could boost hypo-fractionated brachytherapy’s systemic immunomodulatory effects and trigger a distant response.

Hypo-fractionated brachytherapy was more effective in inhibiting tumor growth than external beam radiotherapy. Hypo-fractionated brachytherapy approach significantly influenced various immune cells within the tumor microenvironment, including T cells, DC cells, NK cells, MDSC cells, tumor-associated macrophages. Furthermore, low-dose total body irradiation at 0.1 Gy augmented the immunological effects of low-fractionation brachytherapy and elicited transient systemic immune activation in mice.

Our research indicates that brachytherapy offers superior immune modulation over external radiotherapy. When combined with low-dose total body irradiation, it transiently activates the systemic immune response.

## Linked entities

- **Species:** Mus musculus (taxon 10090)

## Full-text entities

- **Genes:** Cd4 (CD4 antigen) [NCBI Gene 12504] {aka L3T4, Ly-4}, Trex1 (three prime repair exonuclease 1) [NCBI Gene 22040], Itgam (integrin alpha M) [NCBI Gene 16409] {aka CD11b/CD18, CR3, CR3A, Cd11b, F730045J24Rik, Ly-40}, Mrc1 (mannose receptor, C type 1) [NCBI Gene 17533] {aka CD206, MR}, Ifng (interferon gamma) [NCBI Gene 15978] {aka IFN-g, If2f, Ifg}, Apc (APC, WNT signaling pathway regulator) [NCBI Gene 11789] {aka CC1, Min, mAPC}, Itgax (integrin alpha X) [NCBI Gene 16411] {aka Cd11c, Cr4, N418}, Tbk1 (TANK-binding kinase 1) [NCBI Gene 56480] {aka 1200008B05Rik}, Sting1 (stimulator of interferon response cGAMP interactor 1) [NCBI Gene 72512] {aka 2610307O08Rik, ERIS, MPYS, Mita, STING, STING-beta}, Calr (calreticulin) [NCBI Gene 12317] {aka CRT, Calregulin}, Cxcl10 (C-X-C motif chemokine ligand 10) [NCBI Gene 15945] {aka C7, CRG-2, INP10, IP-10, IP10, Ifi10}, Cd86 (CD86 antigen) [NCBI Gene 12524] {aka B7, B7-2, B7.2, B70, CLS1, Cd28l2}, Ly6g (lymphocyte antigen 6 family member G) [NCBI Gene 546644] {aka Gr-1, Gr1, Ly-6G}, H2ax (H2A.X variant histone) [NCBI Gene 15270] {aka H2A.X, H2afx, Hist5-2ax, gammaH2ax}, Il2 (interleukin 2) [NCBI Gene 16183] {aka Il-2}, Klrb1c (killer cell lectin-like receptor subfamily B member 1C) [NCBI Gene 17059] {aka CD161, Klrb1b, Ly-59, Ly55c, Ly59, NK-RP1}, Hmgb1 (high mobility group box 1) [NCBI Gene 15289] {aka HMG-1, Hmg1, SBP-1, p30}, Irf3 (interferon regulatory factor 3) [NCBI Gene 54131] {aka C920001K05Rik, IRF-3}, Cgas (cyclic GMP-AMP synthase) [NCBI Gene 214763] {aka E330016A19Rik, Mb21d1}, Ptprc (protein tyrosine phosphatase receptor type C) [NCBI Gene 19264] {aka B220, CD45R, Cd45, L-CA, Ly-5, Lyt-4}, ITGAM (integrin subunit alpha M) [NCBI Gene 3684] {aka CD11B, CR3A, HNA-4, MAC-1, MAC1A, MO1A}, Hspa1b (heat shock protein family A (Hsp70) member 1B) [NCBI Gene 15511] {aka HSP70B1, Hsp70, Hsp70-1, Hsp70.1, hsp68}, MRC1 (mannose receptor C-type 1) [NCBI Gene 4360] {aka CD206, CLEC13D, CLEC13DL, MMR, MRC1L1, bA541I19.1}, CD8A (CD8 subunit alpha) [NCBI Gene 925] {aka CD8, CD8alpha, IMD116, Leu2, p32}, Il10 (interleukin 10) [NCBI Gene 16153] {aka CSIF, If2a, Il-10}, Mki67 (antigen identified by monoclonal antibody Ki 67) [NCBI Gene 17345] {aka D630048A14Rik, Ki-67, Ki67}, Dnase1 (deoxyribonuclease I) [NCBI Gene 13419] {aka DNaseI, Dnl1}, CD86 (CD86 molecule) [NCBI Gene 942] {aka B7-2, B7.2, B70, BU63, CD28LG2, CD86 v6}, Adgre1 (adhesion G protein-coupled receptor E1) [NCBI Gene 13733] {aka DD7A5-7, EGF-TM7, Emr1, F4/80, Gpf480, Ly71}, Cd3e (CD3 antigen, epsilon polypeptide) [NCBI Gene 12501] {aka CD3, CD3epsilon, T3e}
- **Diseases:** hematopoietic diseases (MESH:D019337), cervical dislocation (MESH:D002575), stomach cancer (MESH:D013274), Lewis lung cancer (MESH:D008175), Tumors (MESH:D009369), ICD (OMIM:252500), melanoma (MESH:D008545), prostate cancer (MESH:D011471), TBI (MESH:D012793), liver cancer (MESH:D006528), breast and colon cancer (MESH:D001943), LLC (MESH:D018827), SIME (MESH:D007154), toxicity (MESH:D064420), metastasis (MESH:D009362), Hematologic toxicity (MESH:D006402), colorectal cancer (MESH:D015179)
- **Chemicals:** L (MESH:D007930), isoflurane (MESH:D007530), 192Ir (MESH:C000615087), Cy5.5 (MESH:C098793), streptomycin (MESH:D013307), Carbon (MESH:D002244), paraffin (MESH:D010232), H (MESH:D006859), formalin (MESH:D005557), CO2 (MESH:D002245), DMEM (-), penicillin (MESH:D010406)
- **Species:** Mus musculus (house mouse, species) [taxon 10090], Homo sapiens (human, species) [taxon 9606]

## Full text

_Full body text omitted from this summary view._ Fetch the complete paper as Markdown: https://tomesphere.com/paper/PMC12953076/full.md

## Figures

7 figures with captions in the complete paper: https://tomesphere.com/paper/PMC12953076/full.md

## References

23 references — full list in the complete paper: https://tomesphere.com/paper/PMC12953076/full.md

---
Source: https://tomesphere.com/paper/PMC12953076